Patients diagnosed with COVID-19 and treated with anakinra: a real-world study in the USA

Anakinra, a recombinant, non-glycosylated human interleukin (IL)-1 receptor antagonist, has been used in real-world clinical practice to manage hyperinflammation in coronavirus disease 2019 (COVID-19). This retrospective, observational study analyses US hospital inpatient data of patients diagnosed...

Descripción completa

Detalles Bibliográficos
Autores principales: Rich, Carly, Eriksson, Daniel, Dolfi, Fabrizio, Jablonska, Katarzyna, Dabbous, Firas, Nazir, Jameel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767882/
https://www.ncbi.nlm.nih.gov/pubmed/35020840
http://dx.doi.org/10.1093/cei/uxab024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767882/
https://www.ncbi.nlm.nih.gov/pubmed/35020840
http://dx.doi.org/10.1093/cei/uxab024

Ejemplares similares